Skip to main content

RAS Mutation clinical trials at UCLA

1 research study open to eligible people

Showing trials for
  • RSC-1255 for Treatment of Patients With Advanced Malignancies

    open to eligible people ages 18 years and up

    RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

    Los Angeles, California and other locations

Our lead scientists for RAS Mutation research studies include .

Last updated: